References

1. https://www.nice.org.uk/guidance/ng28/resources/visual-summary-pdf-10956472093
2. Invokana Summary of Product Characteristics
3. Zaccardi F et al. Diabetes Obes Metab 2016; 18(8): 783-794
4. Perkovic V et al. N Engl J Med 2019; 380(24): 2295-2306
5. Neal B et al. N Engl J Med 2017; 377(7): 644-657
6. Skyler JS. Endocrinol Metab Clin North Am 1996; 25: 243-54
7. Lavalle-González FJ et al. Diabetologia 2013; 56(12): 2582-2592
8. Stolar M. Am J Med 2010;123(Suppl 3): S3–11
9. Stratton IM, et al. BMJ 2000;321:405–12
10. Stenlöf K et al. Diabetes Obes Metab 2013; 15(4): 372-382
11. Perkovic V et al. Lancet Diabetes Endocrinol 2018; 6(9): 691-704
12. Durkin M & Blais J. Diabetes Ther 2021; 12(2): 499-508
13. Cherney DZ et al. Circulation 2014; 129(5): 587-597
14. de Albuquerque Rocha N et al. Diab Vasc Dis Res 2018; 15(5): 375–38
15. Perkovic V et al. Curr Med Res Opin 2015; 31(12): 2219–2231
16. Cefalu WT, et al. Lancet 2013;382;941-50.
17. UKPDS (UK Prospective Diabetes Study), UKPDS 80, N Eng J Med 2008; 359 Holman et al
18. Giorgino F et al. Cardiovasc Diabetol 2020; 19(1): 19
19. Giorgino F et al. Diabetes Obes Metab 2020; 22(9): 1481-1495